Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P1ME
|
||||
| Former ID |
DNCL003834
|
||||
| Drug Name |
MK-3222
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Merck
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-23 ligand | Target Info | [533261] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Toll-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Type I diabetes mellitus | |||||
| Pertussis | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| African trypanosomiasis | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Measles | |||||
| Influenza A | |||||
| Herpes simplex infection | |||||
| Inflammatory bowel disease (IBD) | |||||
| Allograft rejection | |||||
| References | |||||
| Ref 524424 | ClinicalTrials.gov (NCT01936688) A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012). U.S. National Institutes of Health. | ||||
| Ref 542967 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8093). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.